U.S. regulators approve targeted pancreatic cancer drug shown to improve survival rates

https://i.cbc.ca/ais/7dac3321-6fee-478e-bcf2-13ba822c6c32,1787761651911/full/max/0/default.jpg?im=Crop%2Crect%3D%280%2C287%2C5512%2C3100%29%3BResize%3D%28620%29" title="Menta "Steve" Wallace shows a bottle of daraxonrasib, Revolution Medicine?s pancreatic cancer drug, at his home in The Woodlands, Texas, U.S., May 29, 2026.

REUTERS/Danielle Villasana" width="620" />

The U.S. Food and Drug Administration has approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment ‌or cannot receive combination chemotherapy.